Affiliation:
1. Touro University College of Osteopathic Medicine,
2. Touro University Primary Care Department
3. Touro College of Pharmacy
Abstract
Background:
The COVID-19 pandemic necessitated widespread lockdowns, significantly altering daily routines and activity levels. This study hypothesizes that such changes might have exacerbated the health risks associated with type 2 diabetes (T2D).
Objective:
Given the prevalence of T2D among U.S. adults and the centrality of weight gain as a risk factor, this research aims to explore the potential ramifications of the pandemic on TGD risk. Such findings are important for preparations against future outbreaks, which might amplify T2D onset rates.
Methods:
Affiliates from three U.S. Touro college campuses were surveyed to assess the pandemic’s effects on dietary patterns, daily activity levels, and weight change. To gauge changes in T2D risk, a diabetes risk score was determined, comparing pre-pandemic levels to those observed during COVID-19 restrictions. The study used a survey research method and Qualtrics for data collection. The research proposal was approved by the University Institutional Review Board (M-0221).
Results:
Of the participants, 65.9% reported decreased activity levels, while 46.3% experienced weight gain. Notably, 64.2% of participants had an elevated risk score, signifying an increased vulnerability to T2D.
Publisher
American College of Osteopathic Family Physicians of California
Reference15 articles.
1. U.S. Department of Health and Human Services. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention; 2020. (CDC publ. No. CS 314227-A)
2. American Society for Metabolic and Bariatric Surgery. Type 2 Diabetes and Metabolic Surgery [article online]. 2018. Available from: https://asmbs.org/app/uploads/2018/11/Type-2-Diabetes-Fact-Sheet.pdf. Accessed May 15, 2021.
3. Ganz ML, Wintfeld N, Li Q, Alas V, Langer J, Hammer M. The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States. Diabetol Metab Syndr. 2014;6:4.
4. Anderson JE. Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. Diabetes Spectrum. 2020;33(2):165-174.
5. Gatineau M, Hancock C, Holman N, et al. Adult Obesity and Type 2 Diabetes. Oxford: Public Health England, 2014